| scholarly article | Q13442814 |
| P50 | author | Margaret E. Ackerman | Q57012155 |
| Galit Alter | Q88683228 | ||
| Chris Bailey-Kellogg | Q89469549 | ||
| P2093 | author name string | Anna F Licht | |
| Anne-Sophie Dugast | |||
| Ickwon Choi | |||
| Todd Suscovich | |||
| Jennifer I Lai | |||
| P2860 | cites work | ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge | Q27342615 |
| High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples | Q28389941 | ||
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation | Q29417018 | ||
| A whole-genome association study of major determinants for host control of HIV-1 | Q29614891 | ||
| Immune-correlates analysis of an HIV-1 vaccine efficacy trial | Q29617377 | ||
| A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples | Q30498394 | ||
| IgG subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected recipients of Env vaccines | Q33827771 | ||
| Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. | Q34009945 | ||
| Additive contribution of HLA class I alleles in the immune control of HIV-1 infection | Q34120809 | ||
| Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses | Q34982646 | ||
| Effects of thymic selection of the T-cell repertoire on HLA class I-associated control of HIV infection | Q34994754 | ||
| High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers | Q35005192 | ||
| Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family | Q36363231 | ||
| Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity | Q36797342 | ||
| Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques | Q37033311 | ||
| Immunogenetics of spontaneous control of HIV | Q37051202 | ||
| Emerging concepts on the role of innate immunity in the prevention and control of HIV infection | Q37955261 | ||
| A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcγ receptors to define the role of effector functions in protection against HIV. | Q38631835 | ||
| IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease | Q39157800 | ||
| Determining the phagocytic activity of clinical antibody samples | Q39432766 | ||
| Divergent immunoglobulin g subclass activity through selective Fc receptor binding | Q40344836 | ||
| Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b | Q40529181 | ||
| Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers | Q40659603 | ||
| Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients | Q41689302 | ||
| HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression | Q45053138 | ||
| Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8+ T cells associated with HLA-B57/5801 and virus control | Q45373387 | ||
| Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate | Q46775963 | ||
| A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. | Q52841139 | ||
| Combination of HIV‐1–Specific CD4 Th1 Cell Responses and IgG2 Antibodies Is the Best Predictor for Persistence of Long‐Term Nonprogression | Q56837842 | ||
| Elite control of HIV infection: implications for vaccine design | Q56994404 | ||
| Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers | Q60343375 | ||
| Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251 | Q64378954 | ||
| HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression | Q71396764 | ||
| GM phenotypes influence the concentrations of the four subclasses of immunoglobulin G in normal human serum | Q71876491 | ||
| Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection | Q74012651 | ||
| Sustained antibody-dependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS | Q78678676 | ||
| Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannose-binding lectin | Q79929623 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 2799-2809 | |
| P577 | publication date | 2013-12-18 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers | |
| P478 | volume | 88 |
| Q33720317 | A Phase 1 Human Immunodeficiency Virus Vaccine Trial for Cross-Profiling the Kinetics of Serum and Mucosal Antibody Responses to CN54gp140 Modulated by Two Homologous Prime-Boost Vaccine Regimens |
| Q64071431 | Antibody Fab-Fc properties outperform titer in predictive models of SIV vaccine-induced protection |
| Q33867299 | Antiviral Functions of Human Immunodeficiency Virus Type 1 (HIV-1)-Specific IgG Antibodies: Effects of Antiretroviral Therapy and Implications for Therapeutic HIV-1 Vaccine Design |
| Q59808684 | Association of Diverse Genotypes and Phenotypes of Immune Cells and Immunoglobulins With the Course of HIV-1 Infection |
| Q34204325 | Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity |
| Q56974226 | Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy? |
| Q48222733 | Designer α1,6-Fucosidase Mutants Enable Direct Core Fucosylation of Intact N-Glycopeptides and N-Glycoproteins. |
| Q33865785 | Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy |
| Q88792987 | Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity |
| Q36110293 | Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma |
| Q38717198 | Engineering broadly neutralizing antibodies for HIV prevention and therapy |
| Q42675928 | Genetic variants of Fcγ (GM allotypes) and the Fc-mediated effector functions in HIV-1 controllers |
| Q41484708 | HIV microarray for the mapping and characterization of HIV-specific antibody responses |
| Q49963941 | HIV-1 Control and Immunoglobulin Genes |
| Q52598776 | HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies. |
| Q92006869 | IgG3 enhances neutralization potency and Fc effector function of an HIV V2-specific broadly neutralizing antibody |
| Q30362489 | Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure? |
| Q47384731 | Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination |
| Q50209602 | Optimization and qualification of an Fc Array assay for assessments of antibodies against HIV-1/SIV. |
| Q35888710 | Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control |
| Q61811072 | Semen IgM, IgG1, and IgG3 Differentially Associate With Pro-Inflammatory Cytokines in HIV-Infected Men |
| Q30238729 | Systems serology for evaluation of HIV vaccine trials |
| Q46632788 | Temporal variation in HIV-specific IgG subclass Abs during acute infection differentiates spontaneous controllers from chronic progressors. |
| Q40163730 | The association of HIV-1 Gag-specific IgG antibodies with natural control of HIV-1 infection in individuals not carrying HLA-B*57: 01 is only observed in viremic controllers |
| Q34252448 | The dysfunction of T follicular helper cells |
| Q37113972 | The role of Fc receptors in HIV prevention and therapy |
| Q35823060 | Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification |
Search more.